Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 11, 2002, Pages 1265-1268

  Tsukada, Katsuhiko ^a   Miyazaki, T ^a   Katoh, H ^a   Masuda, N ^a   Ojima, H ^a   Fukai, Y ^a   Nakajima, M ^a   Manda, R ^a   Fukuchi, M ^a   Kuwano, H ^a   Tsukada, O ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Haemodialysis; Helicobacter pylori; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; DIAGNOSTIC AGENT; ENZYME INHIBITOR; UREA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BITTER TASTE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOSCOPY; FEMALE; GIEMSA STAIN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMODIALYSIS PATIENT; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING; AGE; BREATH ANALYSIS; CLINICAL TRIAL; DRUG COMBINATION; GASTROSCOPY; KIDNEY DISEASE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETREATMENT; SEX DIFFERENCE; TIME;

AGE FACTORS; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENZYME INHIBITORS; FEMALE; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OMEPRAZOLE; RENAL DIALYSIS; RETREATMENT; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; UREA;

EID: 18644365188     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202761020524     Document Type: Article

References (34)

1. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
2. Graham DY, Go MF. Helicobacter pylori. Current status. Gastroenterology 1993;339:896-7.
3. National Institute of Health Consensus Development Conference Statement. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
4. Pignatelli B, Bancel B, Plummer M, Toyokuni S, Patricot LM, Ohshima H. Helicobacter pylori eradication attenuates oxidative stress in human gastric mucosa. Am J Gastroenterol 2001;96:1758-66.
5. Marchi S, Costa F, Bellini M, Belcari C, Mumolo MG, Tornar A, et al. Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretary therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001;13:547-50.
6. Kao CH, Hsu YH, Wang SJ. Delayed gastric emptying and Helicobacter pylori infection with chronic renal failure. Eur J Nucl Med 1995;22:1282-5.
7. Chachati A, Godon JP. Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant 1987;1:233-7.
8. Korman MG, Laver MC, Hanky J. Hypergastrinaemia in chronic renal failure. Br Med J 1972;272:209-10.
9. Ozugur O, Boyacioglu S, Ozdogan M, Gur G, Telatar H, Haberal M. Helicobacter pylori infection in haemodialysis patients and renal transplant recipients. Nephrol Dial Transplant 1997;12:289-91.
10. Derveniotis V, Koliouskas D, Kalekou H. Campylobacter pylori in severely uremic, hemodialyzed and successfully transplanted patients. Abstracts. XIth International Congress of Nephrology, Tokyo 1990; 138A.
11. Offerhaus GJ, Kreuning J, Valentijn RM, Salvador Pena A, Endtz PH, van Duyn W, et al. Campylobacter pylori: Prevalence and significance in patients with chronic renal failure. Clin Nephrol 1989;32:239-41.
12. Jaspersen D, Fassbinder W, Heinkele P, Kronsbein H, Schorr W, Raschka C, et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in with patients with normal renal function. J Gastroenterol 1995;30:585-8.
13. Ogura K, Yoshida H, Maeda S, Yamaji Y, Kawabe T, Okamoto M, et al. Clarithromycin-based therapy for non-resistant Helicobacter pylori infection. How long should it given? Scand J Gastroenterol 2001;36:584-8.
14. Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbrarao I, De Matthaeis M, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001;15:1193-7.
15. Graham DY, Lew GM, Malaty HM, Evans DG Jr, Klein PD, Alpert LC, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:943-6.
16. Glupczynsky Y, Burettea A. Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am J Gastroenterol 1990;85:1545-51.
17. Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hos Clin Fac Med San Paulo 2001;56:11-16.
18. Hunt R, Thomson AB. Canadian Helicobacter pylori consensus conference. Can J Gastroenterol 1998;12:31-41.
19. Des Verannes SB, Flejou JF, Colin R, Zaim M, Meunier A, Bidaut-Mazel C. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1177-85.
20. Calvet X, Gene E, Lopez T, Gisbert P. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 2001;15:1067-76.
21. Tamura H, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Sekino S, et al. Eradication of Helicobacter pylori in patients with end-stage renal failure under dialysis treatment. Am J Kidney Dis 1997;29:86-90.
22. Munoz deBustillo E, Sanchez Tomero JA, Sanz JC, Moreno JA, Jimenez I, Lopez-Brea M, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998;79:55-60.
23. 13C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis 2000;36:124-9.
24. Tsukada K, Miyazaki T, Katoh H, Yoshikawa M, Masuda N, Ojima H, et al. Relationship between serum urea nitrogen and Helicobacter pylori infection. Hepatogastroenterology. In press.
25. Gladziwa U, Haase G, Handt S, Riehl J, Wietholtz H, Dakshinamurty KV, et al. Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transplant 1993;8:301-6.
26. Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1986;22:372-6.
27. Conz P, Chiaramonte S, Ronco C, Feriani M, La Greca G. Campylobacter pylori in uraemic dialyzed patients. Nephron 1989;53:90.
28. Ogihara A, Kikuchi S, Hasegawa A, Kurosawa M, Miki K, Kaneko E, et al. Relationship between Helicobacter pylori infection and smoking and drinking habits. J Gastroenterol Hepatol 2000;15:271-6.
29. Kashiwagi T, lino Y, Sakaki N, Terashi A. Importance of Helicobacter pylori infection and pepsinogen titer in hemodialysis and renal transplant patients in Japan. Nippon Jinzo Gakkai shi 1994;36:853-7.
30. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999;341:1106-11.
31. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
32. Ota K, Yamashita N, Suzuki T, Agishi T. Malignant tumours in dialysis patients: A nationwide survey. Proc Eur Dial Transplant Assoc 1981;18:724-30.
33. 13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: A multicenter study. Am J Gastroenterol 2000;95:646-50.
34. Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori infection and assess success of eradication therapy in hemodialysis patients. Am J Kidney Dis 2001;38:98-103.